Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children

被引：31

作者：

Chokephaibulkit, K. ^{[1
]}

Houillon, G. ^{[2
]}

Feroldi, E. ^{[3
]}

Bouckenooghe, A. ^{[4
]}

机构：

[1] Mahidol Univ, Dept Pediat, Fac Med, Siriraj Hosp, 2 Wanglang Rd, Bangkok 10700, Thailand

[2] Sanofi Pasteur, Global Med Affairs, Lyon, France

[3] Sanofi Pasteur, Clin Dev, Lyon, France

[4] Sanofi Pasteur, Asia Reg Med Affairs & Clin Dev, Singapore, Singapore

来源：

EXPERT REVIEW OF VACCINES | 2016年 / 15卷 / 02期

关键词：

Japanese encephalitis; vaccines; IMOJEV (R); pediatrics; flaviviridae; JE-CV; IMMUNIZATION PROGRAM; IMMUNE-RESPONSE; DOUBLE-BLIND; PHASE-II; RECOMBINANT; CHIMERIVAX(TM); CONCOMITANT; TODDLERS; ADULTS;

D O I：

10.1586/14760584.2016.1123097

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

JE-CV (IMOJEV (R), Sanofi Pasteur, France) is a live attenuated virus vaccine constructed by inserting coding sequences of the prM and E structural proteins of the Japanese encephalitis SA14-14-2 virus into the genome of yellow fever 17D virus. Primary immunization with JE-CV requires a single dose of the vaccine. This article reviews clinical trials of JE-CV in children aged up to 6years conducted in countries across South-East Asia. Strong and persistent antibody responses were observed after single primary and booster doses, with 97% of children seroprotected up to five years after booster vaccination. Models of long-term antibody persistence predict a median duration of protection of approximately 30years after a booster dose. The safety and reactogenicity profiles of JE-CV primary and booster doses are comparable to other widely used childhood vaccines.

引用

页码：153 / 166

页数：14

共 38 条

[1]

[Anonymous], 2015, Wkly Epidemiol Rec, V90, P69

[2]

[Anonymous], 1998, Wkly Epidemiol Rec, V73, P337

[3] IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine [J].

Appaiahgari, Mohan Babu ;

Vrati, Sudhanshu .

EXPERT REVIEW OF VACCINES, 2010, 9 (12) :1371-1384

[4]

Arai S, 2008, JPN J INFECT DIS, V61, P333

[5] Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India [J].

Bonaparte, Matthew ;

Dweik, Bashir ;

Feroldi, Emmanuel ;

Meric, Claude ;

Bouckenooghe, Alain ;

Hildreth, Stephen ;

Hu, Branda ;

Yoksan, Sutee ;

Boaz, Mark .

BMC INFECTIOUS DISEASES, 2014, 14

[6] Estimated global incidence of Japanese encephalitis: a systematic review [J].

Campbell, Grant L. ;

Hills, Susan L. ;

Fischer, Marc ;

Jacobson, Julie A. ;

Hoke, Charles H. ;

Hombach, Joachim M. ;

Marfin, Anthony A. ;

Solomon, Tom ;

Tsai, Theodore F. ;

Tsu, Vivien D. ;

Ginsburg, Amy S. .

BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2011, 89 (10) :766-774

[7] Yellow fever Japanese encephalitis chimeric viruses: Construction and biological properties [J].

Chambers, TJ ;

Nestorowicz, A ;

Mason, PW ;

Rice, CM .

JOURNAL OF VIROLOGY, 1999, 73 (04) :3095-3101

[8]

Chokephaibulkit K, 2014, 7 AS C PED INF DIS A

[9] Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2-to 5-year-olds and Naive 12-to 24-month-olds Multicenter Randomized Controlled Trial [J].

Chokephaibulkit, Kulkanya ;

Sirivichayakul, Chukiat ;

Thisyakorn, Usa ;

Sabchareon, Arunee ;

Pancharoen, Chitsanu ;

Bouckenooghe, Alain ;

Gailhardou, Sophia ;

Boaz, Mark ;

Feroldi, Emmanuel .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (12) :1111-1117

[10] Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine [J].

Desai, Kamal ;

Coudeville, L. ;

Bailleux, F. .

VACCINE, 2012, 30 (15) :2510-2515

← 1 2 3 4 →